Celecoxib

Licensed by Pfizer Catalog No.S1261 Synonyms: SC 58635

Molecular Weight(MW): 381.37

Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Size

Price

Stock

Quantity

100mg	USD 97	In stock
Bulk Size	Bulk Discount

Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck USA Tel: (832) 582-8158 [email protected]

Cited by 23 Publications

J Cancer Res Clin Oncol, 2019, 145(6):1495-1507

PubMed: 31028540 ( click the link to review the publication )

Endocr J, 2019, 10.1507/endocrj.EJ19-0015

PubMed: 31105125 ( click the link to review the publication )

Sci Transl Med, 2018, 10(433)

PubMed: 29563317 ( click the link to review the publication )

Oncol Lett, 2018, 16(1):317-325

PubMed: 29928417 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(10):1274-1285

PubMed: 28892080 ( click the link to review the publication )

Cancer Res, 2017, 77(3):790-801

PubMed: 27940576 ( click the link to review the publication )

Theranostics, 2017, 7(5):1389-1406

PubMed: 28435473 ( click the link to review the publication )

J Transl Med, 2017, 15(1):46

PubMed: 28231855 ( click the link to review the publication )

Biomed Pharmacother, 2017, 89:1235-1241

PubMed: 28320090 ( click the link to review the publication )

J Pharm Biomed Anal, 2017, 145:586-592

PubMed: 28783595 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 490(2):567-573

PubMed: 28624453 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2017, 1861(2):264-275

PubMed: 27894925 ( click the link to review the publication )

J Pharm Sci, 2016, 105(3):1113-23

PubMed: 26886329 ( click the link to review the publication )

Oncotarget, 2016, 7(35):57077-57085

PubMed: 27494851 ( click the link to review the publication )

J Biol Chem, 2015, 290(52):30988-1002

PubMed: 26518876 ( click the link to review the publication )

J Cell Physiol, 2015, 230(5):1115-27

PubMed: ( click the link to review the publication )

Int J Pharm, 2015, 496(2):382-91

PubMed: 26468038 ( click the link to review the publication )

Drug Des Devel Ther, 2015, 9:5851-62

PubMed: 26586936 ( click the link to review the publication )

Biochem Bioph Res Co, 2015, 10.1016/j.bbrc.2015.03.008

PubMed: 25770423 ( click the link to review the publication )

Anticancer Res, 2015, 35(5):2699-708

PubMed: 25964548 ( click the link to review the publication )

Br J Pharmacol, 2014, 171(2):498-508

PubMed: 24372551 ( click the link to review the publication )

J Cell Physiol, 2014, 10.1002/jcp.24919

PubMed: 25546329 ( click the link to review the publication )

Blood, 2011, 118(22):5891-900

PubMed: 21865341 ( click the link to review the publication )

Purity & Quality Control

Choose Selective COX Inhibitors

Biological Activity

Description

Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Targets

COX-2 ^[1]
(Sf9 cells)

40 nM

In vitro

Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. ^[1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
A549	NHPkPIFHfW6ldHnvckBCe3OjeR?=	MnzNNE4yNTNyIN88US=>	NFHBS2U1QCCq		M374Rolv\HWlZYOgTWNCVS1zIHX4dJJme3Orb36gc44h[m:2aDDwdo91\WmwIHHu[EBuWk6DIHzleoVt	M1u5eFI3PTF\|MUey
H460	NV\hOo5ETnWwY4Tpc44hSXO\|YYm=	MV:wMlEuOzBizszN	MVK0PEBp		MWjpcoR2[2W\|IFnDRW0uOSCneIDy[ZN{cW:wIH;uJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcC=>	M2SxfFI3PTF\|MUey
HKESC-2	NVPtTWhXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXrKfYFtOjEEoN88US=>	NHfXeFg1QMLiaNMg		M3qxUpNq\26rZnnjZY51dHliaX7jdoVie2W\|IITo[UBKSzVywrD2ZYx2\XNib3[gc5hidGmybHH0bY7DqA>?	MnjPNlY1PzR4OUO=
CaES-17	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWjUeo5wOjEEoN88US=>	M{f2[FQ5yqCqwrC=		NV3jcYp6e2mpbnnmbYNidnSueTDpcoNz\WG\|ZYOgeIhmKEmFNUFCpJZidHWnczDv[kBwgGGuaYDsZZRqdsLi	M{PsUVI3PDd2Nkmz
HKESC-2	Mki5RZBweHSxc3nzJGF{e2G7	M1e4TlIxyqEQvF2=	MXq0POKhcMLi		NIr3NYVz\WS3Y3XzJI95[WyrcHzheIlvNWmwZIXj[YQh[XCxcITvd4l{	NE\zUogzPjR5NE[5Ny=>
CaES-17	NW\hTVRjSXCxcITvd4l{KEG\|c3H5	M{LGclIxyqEQvF2=	NVq4fZJoPDkEoHlCpC=>		MX;y[YR2[2W\|IH;4ZYxqeGyjdHnuMYlv\HWlZXSgZZBweHSxc3nz	M3vtTlI3PDd2Nkmz
A549	M3;U[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3jGfVUuOTZyIN88US=>	NH[xZ3Y1QMLiaNMg	MnXzSG1UVw>?	MYnJR\|UxRTF4Mz60JO69VQ>?	M1LGPFI3PDZ2NkSz
HCC827	MnrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\pOU0yPjBizszN	MVW0POKhcMLi	M4OzU2ROW09?	M{HUWGlEPTB;NkmuNkDPxE1?	NGH6[YIzPjR4NE[0Ny=>
A549	NXvqN5dJSXCxcITvd4l{KEG\|c3H5	MVS4NEDDvU1?	MkmxOFjDqGkEoB?=	MWrEUXNQ	NETweIpqdmS3Y3XzJIFxd3C2b4Ppdy=>	MVKyOlQ3PDZ2Mx?=
HCC827	M{LPd2Fxd3C2b4Ppd{BCe3OjeR?=	MnPIPFAhyrWP	NXH0O\|BZPDkEoHlCpC=>	M{HXcGROW09?	MUfpcoR2[2W\|IHHwc5B1d3Orcx?=	MlfmNlY1PjR4NEO=
SGC-7901/DDP	MkDiSpVv[3Srb36gRZN{[Xl?	MoroNVDDqML3TR?=	NUO2NGQ{OjRiaB?=		NUPUXFY4cW6qaXLpeJMh[3mlbH;vfJlo\W6jc3WtNkBidmRiUD3ncJlkd3C{b4TlbY4h\XiycnXzd4lwdg>?	M1nHbFI3PDB5NkWz
SGC-7901	NF;pWm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3P0[\|I1yqCqwrC=		NEDGUGNKSzVyPUGxOU4xQCEQvF2=	NEfHc3UzPjRyN{[1Ny=>
SGC-7901/DDP	NHXJZ\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHTJNWszPMLiaNMg		MUHJR\|UxRTN3LkS1JO69VQ>?	NX;1foo6OjZ2MEe2OVM>
SGC-7901/DDP	NFi1dnpCeG:ydH;zbZMhSXO\|YYm=	NE\tblEyOMLiwsXN	MWeyOEBp		Mln1bY5lfWOnczDhdI9xfG:\|aYOgZ49u[mmwZXSge4l1cCC5aYToJINqe3CuYYTpci=>	Mlq5NlY1ODd4NUO=
SGC-7901/DDP	MVrGeY5kfGmxbjDBd5NigQ>?	NX;4fllbOTEEoNM1US=>	NEXwVWIzPCCq		NHPLTlZqdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kBRNWeueXPvdJJwfGWrbjD0bJJwfWeqIHLsc4NscW6pIFXQNkwh[W6mIHnuZYN1cX[jdHnu[{BRU0FiYX7kJGNTTUMEoB?=	Mn\uNlY1ODd4NUO=
SGC-7901/DDP	NYDSflJ2TnWwY4Tpc44hSXO\|YYm=	Mo[0NVDDqML3TR?=	M3PjVlI1KGh?		NHHWNJNk[XW\|ZYOgZUBu[XKtZXSg[IVkemWjc3WgbY4hfGinIHzleoVtKG:oIFLjcE0zKHC{b4TlbY4>	MWCyOlQxPzZ3Mx?=
H357	NGLzenVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV2yZ2cyPy53L{GwJO69VQ>?	NEizb4g1QCCq	NGfGZWxFVVOR	NGrZT\|ZqdmirYnn0d{Bk\WyuIHfyc5d1cMLiY3;tZolv\WRid3n0bEBU[WK3dH;jcIF5	NHHjdogzPjByOUi3OC=>
TAF	NUnEO4pHTnWwY4Tpc44hSXO\|YYm=	MorUNVDDqML3TR?=	NW\TXVF5PyCm		MlHhZYZn\WO2czDURWZ{KGGmaHXzbZZmKHC{b4DldpRq\XN?	NWXTO3U5OjV7OEexNlc>
TAF	MkDoSpVv[3Srb36gRZN{[Xl?	MnnqNVDDqML3TR?=	Mnj1N\|AuOTJyIH3pci=>		MmnGdI9wemy7IHHm[oVkfHNiZFHreEBxcG:\|cHjvdplt[XSrb36gZ49ve2WzdXXueEB1dyCHR1[gd4lodmGuaX7n	NUjsNYVCOjV7OEexNlc>
TAF	MnTtSpVv[3Srb36gRZN{[Xl?	NWn3eJY3OTEEoNM1US=>	M4HCbVQ5KGh?		NEPwbZVqdmO{ZXHz[ZMhTUeIUjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36=	MXGyOVk5PzF{Nx?=
PANC-1	NVTsVmNMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvkNYgzOC94MD:xNFAh\|ryP	NVLhcpp6OjRxNEivO\|IhcA>?		NFG3ZWpqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	NYXwfldEOjV7N{OwOlI>
PANC-1	NU\3eGRWTnWwY4Tpc44hSXO\|YYm=	M2rwXFIxNzZyL{GwNEDPxE1?	MXSyOEBp		MY\heJRmdnWjdIOgZ4VtdCCrbo\hd4lwdiCjbnSgcYloemG2aX;uJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXyxsA>	MWCyOVk4OzB4Mh?=
HeLa	NEPmVlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1zqSVIxyqEQvF5CpC=>	NGrWN2szPMLiaB?=		MWDlcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdg>?	M1HVXVI2PzdyNEKz
SACC-83	M17Xe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{fJWlIxyqEQvF5CpC=>	M4rnbVI1yqCq		NYTuelNn\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36=	MmjMNlU4PzB2MkO=
HeLa	NF3mSXJCeG:ydH;zbZMhSXO\|YYm=	NGS1cmEzOMLizszNxsA>	M1vMWVI1yqCq		NGnBS49mdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBqdmirYnn0bY9vKG:oIHPlcIwh[XCxcITvd4l{	NV34WWVNOjV5N{C0NlM>
SACC-83	NV3JNpBXSXCxcITvd4l{KEG\|c3H5	NVK2NIRjOjEEoN88UeKh	MlnGNlTDqGh?		MmDv[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgbY5pcWKrdHnvckBw\iClZXzsJIFxd3C2b4Ppdy=>	MYqyOVc4ODR{Mx?=
HeLa	NH7KclFHfW6ldHnvckBCe3OjeR?=	NGnTeogzOC92MD:4NEDPxE1?	NEDi[G4zPMLiaB?=		NVviV\|Y1fXC{ZXf1cIF1eyCSVFXOJJBienSrYXzsfUBjgSCrbnjpZol1cW6pIGPwNUwh[W6mIHHjeIl3[XSnczDQWGVPKGGwZDDpcoFkfGm4YYTld{BCU1R?	NUn5dGFDOjV5N{C0NlM>
SACC-83	NWOybVI4TnWwY4Tpc44hSXO\|YYm=	MlrFNlAwPDBxOECg{txO	NGHmUnIzPMLiaB?=		MVL1dJJm\3WuYYTzJHBVTU5icHHyeIlidGy7IHL5JIlvcGmkaYTpcochW3BzLDDhcoQh[WO2aY\heIV{KFCWRV6gZY5lKGmwYXP0bZZifGW\|IFHLWC=>	NFnJTW0zPTd5MESyNy=>
HLCZ01	NEXvbnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHrCS\|cx6oDVNkFCpOK2VQ>?	NYjoPItNPDhiaB?=	MV7EUXNQ	MWTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	NXjmd5A{OjV5MkS4PVk>
HLCZ01	NFLZd2hHfW6ldHnvckBCe3OjeR?=	NW[0SYlpPDEEoN88US=>	NIq3fmQzPCCq	MkLDSG1UVw>?	NV;2cZJ7cW6lcnXhd4V{KGGlY4XteYxifGmxbjDv[kBIOC:JMT3wbIF{\SClZXzsd{Bkd22kaX7l[EB4cXSqIFnGUk3PuQ>?	NF74bYczPTd{NEi5PS=>
HLCZ01	NFr1[nBCeG:ydH;zbZMhSXO\|YYm=	MWW0NOKh\|ryP	NEPBRmszPCCq	NG\BW5FFVVOR	Mnzh[Y5p[W6lZYOgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiSV\OMe6y	MU[yOVczPDh7OR?=
HLCZ01	MkfDSpVv[3Srb36gRZN{[Xl?	MlTyOFDDqM7:TR?=	M2XUNVI1KGh?	M2TNXWROW09?	MXfpcoNz\WG\|ZYOgWHJCUUxiZYjwdoV{e2mxbjDjc41jcW6nZDD3bZRpKEmwdHXy[oVzd25vzsG=	M1LielI2PzJ2OEm5
MGC803	NETlSmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4SyW\|AuPjBizszN	NVH0OHloPzJiaB?=		MkPMTWM2OD12Nz6yOgKBkcLz4pEJOk41OyEQvF2=	NHfLUHIzPTdyMUO3PC=>
SGC7901	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHnQVnIxNTZyIN88US=>	NVfPNox7PzJiaB?=		MnroTWM2OD12Mz61N-KBkcLz4pEJOU4yOiEQvF2=	MVKyOVcxOTN5OB?=
MGC803	NEnGNZJHfW6ldHnvckBCe3OjeR?=	NFTUcFE1OMLizszN	M4rNVVgwOTZxMkSgbC=>		NYHrcXpZfXC{ZXf1cIF1eyCFYnytZkBmgHC{ZYPzbY9v	MXWyOVcxOTN5OB?=
SGC7901	MmrzSpVv[3Srb36gRZN{[Xl?	NUPoOmJPPDEEoN88US=>	M1njcVgwOTZxMkSgbC=>		MnnpeZBz\We3bHH0d{BE[mxvYjDlfJBz\XO\|aX;u	NV3wWoFVOjV5MEGzO\|g>
MCF-7	NWK4eVhvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYXNWIk3OS9zMDFOwG0>	Ml3GO\|IhcA>?	NXG1[Zl[TE2VTx?=	MmLx[Y5p[W6lZYOgZ4Ft[2m2cnnvcE1qdmS3Y3XkJINmdGxiZ4Lve5RpKGmwaHnibZRqd25?	MVSyOVY3PzVzMB?=
MDA-MB-231	MoHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV72dJhuOS9zMDFOwG0>	NUjTbHFqPzJiaB?=	MYnEUXNQ	NF7qVYVmdmijbnPld{Bk[WylaYTybY9tNWmwZIXj[YQh[2WubDDndo94fGhiaX7obYJqfGmxbh?=	NWj0eoRIOjV4Nke1NVA>
MDA-MB-231	M4e0c2Z2dmO2aX;uJGF{e2G7	M3f1U\|AuPDBiwsXN	NITxPFQ1NTJ2IHi=		NV;LfplvcW6lcnXhd4V{KEORWD2yJJBzd3SnaX6g[ZhxemW\|c3nvckBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	NFOwXVgzPTV6N{OyPS=>
MCF-7	NHzVZ2dHfW6ldHnvckBCe3OjeR?=	NID6W5YxNTRyINM1US=>	M1v2OVQuOjRiaB?=		M{nROYVvcGGwY3XzJJRp\SCnZn\lZ5R{KG:oIGTQRUBwdiCDQlPHNkBmgHC{ZYPzbY9vyqB?	NE\GdlYzPTV6N{OyPS=>
MCF7-MX	NFPEZoFHfW6ldHnvckBCe3OjeR?=	MXewMVQxKML3TR?=	NGDEWFk1NTJ2IHi=		Mmfr[Y5p[W6lZYOgeIhmKGWoZnXjeJMhd2ZiVGDBJI9vKEGEQ1eyJIV5eHKnc4Ppc47DqA>?	Ml;VNlU2QDd\|Mkm=
MDA-MB-231	NVm2RlBYTnWwY4Tpc44hSXO\|YYm=	MWOwMVQxKML3TR?=	M3fTS\|QuOjRiaB?=		NIm3cWZ{fGmvdXzheIV{KHSqZTDlfJBz\XO\|aX;uJI9nKEGEQ1eyJJVxKHSxIESuNlchfGmvZYOgeI8h[2:wdILvcEBt\X[nbDDifUAyOiCqwrC=	NFfMOGQzPTV6N{OyPS=>
A2780	M{O3W2Z2dmO2aX;uJGF{e2G7	MVW1M\|ExNzF3IN88US=>	MXW0PEBp		NY\WeZcy\GWlcnXhd4V{KEOxeD2yJIV5eHKnc4Ppc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NUnNW2ZqOjV2MkS4PVg>
SKOV3	M1j3TWZ2dmO2aX;uJGF{e2G7	NXXmWZNHPS9zMD:xOUDPxE1?	NULzPW1vPDhiaB?=		NGD2WJBl\WO{ZXHz[ZMhS2:6LUKg[ZhxemW\|c3nvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	M4Tkd\|I2PDJ2OEm4
A2780	M3HrbGZ2dmO2aX;uJGF{e2G7	M{Lqe\|UwOTBxMUWg{txO	NXfEblhQPDhiaB?=		NVH4NY5Q\WyndnH0[ZMhfGinIHX4dJJme3Orb36gc4YhTS2lYXTo[ZJqdiCjbnSgb4Vz[XSrbh?=	M4XnfVI2PDJ2OEm4
SKOV3	NW[3N3NzTnWwY4Tpc44hSXO\|YYm=	MVW1M\|ExNzF3IN88US=>	M4rxRVQ5KGh?		MVrlcIV3[XSnczD0bIUh\XiycnXzd4lwdiCxZjDFMYNi\GincnnuJIFv\CCtZYLheIlv	MlLuNlU1OjR6OUi=
A2780	NFvlclFHfW6ldHnvckBCe3OjeR?=	MlixOU8yOC9zNTFOwG0>	NU\aXFBLPDhiaB?=		MVjk[YNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ib3[gUk1k[WSqZYLpckBidmRiVnnt[Y51cW5?	NGntNXczPTR{NEi5PC=>
SKOV3	MWjGeY5kfGmxbjDBd5NigQ>?	MmDMOU8yOC9zNTFOwG0>	MUm0PEBp		NFHBbFZl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhVi2lYXTo[ZJqdiCjbnSgWolu\W62aX6=	MW[yOVQzPDh7OB?=
A2780	M3LJTGZ2dmO2aX;uJGF{e2G7	NX\hO4hTPS9zMD:xOUDPxE1?	NE[2XnMyKGh?		M1vEdolv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBxNUGNVDDhcoQheC2HUlugbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	M3njblI2PDJ2OEm4
SKOV3	MYnGeY5kfGmxbjDBd5NigQ>?	MUC1M\|ExNzF3IN88US=>	M2jDRlEhcA>?		MkHObY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJJAuSUuWIHHu[EBxNUWUSzDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	M1raRVI2PDJ2OEm4
HCT-15	MlvaSpVv[3Srb36gRZN{[Xl?	M2H6RlExNTVyIN88US=>	NF:4b\|I3NTN4IHi=		NEfvd5NqdmS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mJGNQYC1{IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy	M1\ibFI2OjF6MEK4
HT-29	Mne2SpVv[3Srb36gRZN{[Xl?	NHPoUWcyOC13MDFOwG0>	NXvpVnNxPi1\|NjDo		NHniRpNqdmS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mJGNQYC1{IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy	MmO2NlUzOThyMki=
HSC3	NH:zTHVE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NIO3[IMx6oDVNECg{txO	NGO1[2I1QCCq		NH\DZ2ZKSzVyPUK1MlXDuTFwN{iwJO69VQ>?	MUiyOVE6QDd6OR?=
HSC3	MkTVRZBweHSxc3nzJGF{e2G7	NVPoTHc5OjVizszN	NIj0VXo1QCCq		MmrvbY5lfWOnczDhdI9xfG:\|aYO=	NYn6VFUyOjVzOUi3PFk>
HSC3	NIP0fI5HfW6ldHnvckBCe3OjeR?=	MViyOUDPxE1?	MoD5OFghcA>?		NYf3folU\XiqaXLpeJMhe2mpbnnmbYNidnSueTDy[YR2[2WmIH3p[5JifGmxbjDjc41jcW6nZDD3bZRpKEOHVB?=	NIfROIYzPTF7OEe4PS=>
HSC3	NWjaXmxGTnWwY4Tpc44hSXO\|YYm=	MXWyOUDPxE1?	NW\GRmdEPDhiaB?=		MVvpcohq[mm2czDIV2M{KGOnbHygbY53[XOrb36gZ49u[mmwZXSge4l1cCCFRWS=	NUHPO3FVOjVzOUi3PFk>
HSC3	MkPRSpVv[3Srb36gRZN{[Xl?	MlvmNlUh\|ryP	Ml65O\|IhcA>?		NVH2ZXY3\GWlcnXhd4V{KE2PUD2yJIFv\CCPTWCtPUBxem:2ZXnud:Kh	Mo\HNlUyQTh5OEm=
201T	MmO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NH\keGw4OiCq	NH\XNHVFVVOR	NF\zUIlKSzVyPUS4MlYhyrWP	MlGzNlUxPTd7NEG=
273T	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MX63NkBp	M17rU2ROW09?	NVT3XJlxUUN3ME24NE42KML3TR?=	MXqyOVA2Pzl2MR?=
Hep-2	NE[wOI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYezNE82OC9zMECg{txO	MonrNVIwOjRxM{[vOFghcA>?	NGDXdXBFVVOR	NYfMcYhIcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	NVvESIxtOjR7OUi1OlQ>
Hep-2	MoLPRZBweHSxc3nzJGF{e2G7	MVi1NEDPxE1?	NYfKN4p2OC12ODDo	M2ftdWROW09?	M3jtTolv\HWlZYOgZZBweHSxc3nzJIlvKGFidHnt[UBl\XCnbnTlcpQhdWGwbnXy	NY\GeHZsOjR7OUi1OlQ>
Hep-2	NFXUV25HfW6ldHnvckBCe3OjeR?=	NYm2WnVGPTBizszN	M4TyRlAuPDhiaB?=	MV\EUXNQ	MlLpdoVlfWOnczD0bIUhfGWub33ldoF{\SCjY4Tpeol1gSCpcnHkeYFtdHl?	MnezNlQ6QTh3NkS=
Hep-2	MWXGeY5kfGmxbjDBd5NigQ>?	M1HES\|UxKM7:TR?=	NGjEOIwxNTR6IHi=	MXTEUXNQ	MlPW[IVkemWjc3XzJJRp\SCvUl7BJIV5eHKnc4Ppc44hd2ZiaGTFVnQ>	NIXCT5UzPDl7OEW2OC=>
SGC-7901	M4nuTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmjkNVAwPTBxMUCwJO69VQ>?	Ml[zNlQwPDhxN{KgbC=>	M4XiRWROW09?	NYnhNpdLcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	MXqyOFk6Ojl3OB?=
MKN-45	M{ToSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vMWVExNzVyL{GwNEDPxE1?	MXmyOE81QC95MjDo	M3rVNWROW09?	M1PudolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	MlP4NlQ6QTJ7NUi=
SGC-7901	M3fnc2Z2dmO2aX;uJGF{e2G7	NFi5fFgyOC93MD:xNFAh\|ryP	MnfiOFghcA>?	MnK2SG1UVw>?	MUnkc5dvemWpdXzheIV{KHSqZTDtVm5CKGW6cILld5Nqd25ibHX2[Yx{KG:oIFPPXE0zKGGwZDDQR25CKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	Ml3KNlQ6QTJ7NUi=
MKN-45	M4TqRWZ2dmO2aX;uJGF{e2G7	NVXNRZpYOTBxNUCvNVAxKM7:TR?=	NX:zUoxDPDhiaB?=	NFTWRYJFVVOR	NIS5fpZld3ewcnXneYxifGW\|IITo[UBuWk6DIHX4dJJme3Orb36gcIV3\Wy\|IH;mJGNQYC1{IHHu[EBRS06DIHnuJIEh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	NULhR2R[OjR7OUK5OVg>
C666-1	MXHDfZRwfG:6aXPpeJkhSXO\|YYm=	NEjvSIUzOC16MDFOwG0>	Mn;wNlQhcA>?		M1mzWoRm[3KnYYPld{Bkd2yxbomg[o9zdWG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyxsA>	NX\Me2h7OjR6NUS4N\|g>
CNE-1	MnfaR5l1d3SxeHnjbZR6KEG\|c3H5	M3jXT\|IxNThyIN88US=>	NWXuZ2U4OjRiaB?=		M16wWoRm[3KnYYPld{Bkd2yxbomg[o9zdWG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyxsA>	MkXXNlQ5PTR6M{i=
CNE-2	Ml;1R5l1d3SxeHnjbZR6KEG\|c3H5	NVvGdHdPOjBvOECg{txO	NH[0S48zPCCq		M3;CfIRm[3KnYYPld{Bkd2yxbomg[o9zdWG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyxsA>	NEXmRngzPDh3NEizPC=>
C666-1	MmK4R5l1d3SxeHnjbZR6KEG\|c3H5	MmTMOlAh\|ryP	NIiwR404KGR?		M4L0UoVvcGGwY3XzJJJi\GmjdHnvckBkgXSxdH;4bYNqfHlidHjyc5VocCCFT2itNk1l\XCnbnTlcpQhdWGwbnXy	MY[yOFg2PDh\|OB?=
CNE-1	MnrPR5l1d3SxeHnjbZR6KEG\|c3H5	M3nKVlYxKM7:TR?=	M1fTWlch\A>?		MYnlcohidmOnczDyZYRq[XSrb36gZ5l1d3SxeHnjbZR6KHSqcn;1[4ghS0:[LUKt[IVx\W6mZX70JI1idm6nch?=	MYeyOFg2PDh\|OB?=
SNU-1041	NYPWWoRtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoX5NE01OCEQvF2=	MU[0PEBp		MnLVbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	M4XoXFI1Pjl{N{Cz
SNU-1041	NYW2SnZUTnWwY4Tpc44hSXO\|YYm=	MUWyNE8{OCEQvF2=	Mm\ROEBp		NELzfWVqdmS3Y3XzJIV5eHKnc4Ppc44hd2cEoFPIU3AtKEeUUEe4xsBidmUEoGjCVFHDqGG2IITo[UBTVkFibHX2[YzDqA>?	MUCyOFY6OjdyMx?=
SNU-1041	M4[0O2Z2dmO2aX;uJGF{e2G7	MUSwMVQxKM7:TR?=	MXW0JIg>		M1vqW5VxNXKnZ4XsZZRmeyCFSF;QxsBi\nSncjD0doVifG2nboSge4l1cCCqaXfoJINwdmOnboTyZZRqd26\|	MVWyOFY6OjdyMx?=
SGC-7901	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2C2cFUxNTF{NTFOwG0>	Ml\TNlQwPDhxN{KgbC=>		M1\HO4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	Ml7BNlQ3PzZ\|OUS=
SGC-7901	NH3MW4pCeG:ydH;zbZMhSXO\|YYm=	MmrINVAxKM7:TR?=	Ml\PO\|IhcA>?		M175d4lv\HWlZYOgZZBweHSxc3nz	NV7MWo9tOjR4N{[zPVQ>
SGC-7901	NUfjS\|h5TnWwY4Tpc44hSXO\|YYm=	Mo\vO\|UwOTByL{GyOUDPxE1?	MWOyOE81QC95MjDo		M33ZZ4lv[3KnYYPld{Bk[XOyYYPlMVgh[W6mID25JI1TVkFiZYjwdoV{e2mxbjDpckBjd3SqIITpcYUh[W6mIHTvd4UhdWGwbnXy	MXyyOFY4PjN7NB?=
LMeC	M{\pPWZ2dmO2aX;uJGF{e2G7	NV\sOm9SOjBxNUCg{txO	Mo\2OFghcA>?		MXTk[YNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ib3[gR29ZNTJicILveIVqdg>?	MYCyOFY2Pjd2Nh?=
CMeC-1	MmLER4VtdCCYaXHibYxqfHliQYPzZZk>	MmjaNlAwPTBizszN	MnrzOFghcA>?		Mmq1bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NHHGOXMzPDZ3Nke0Oi=>
LMeC	NVTLNVdIS2WubDDWbYFjcWyrdImgRZN{[Xl?	NHXQbYQzOC93MDFOwG0>	MYO0PEBp		NV3uSmZscW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	MkLBNlQ3PTZ5NE[=
CMeC-1	NWrYNHhvTnWwY4Tpc44hSXO\|YYm=	MnXsNlAwPTBizszN	MVy0PEBp		MVjpcoR2[2W\|IFexMXMh[XK{ZYP0	M3LSU\|I1PjV4N{S2
LMeC	NFnUfXFHfW6ldHnvckBCe3OjeR?=	NIjkToUzOC93MDFOwG0>	M4LwUFQ5KGh?		MUPpcoR2[2W\|IFexMXMh[XK{ZYP0	M{DaNFI1PjV4N{S2
CMeC-1	M1vZRWZ2dmO2aX;uJGF{e2G7	NV\0TYw5OjBxNUCg{txO	M{jCUFQ5KGh?		M3\ZRYRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIHP5Z4xqdiCGMTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NWjjV5ZnOjR4NU[3OFY>
LMeC	NXHYdGdQTnWwY4Tpc44hSXO\|YYm=	M3n3fVIxNzVyIN88US=>	M1vlW\|Q5KGh?		M4HlNYRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIHP5Z4xqdiCGMTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MUiyOFY2Pjd2Nh?=
CMeC-1	NILI[4tHfW6ldHnvckBCe3OjeR?=	NG\KVlgzOC93MDFOwG0>	MnGyOFghcA>?		NI\5WIxqdmS3Y3XzJINie3Cjc3WtN{Bi[3SrdnH0bY9v	NF;BdWszPDZ3Nke0Oi=>
LMeC	M3joVGZ2dmO2aX;uJGF{e2G7	NYXYS5VNOjBxNUCg{txO	NXHNUVdEPDhiaB?=		MkHjbY5lfWOnczDjZZNx[XOnLUOgZYN1cX[jdHnvci=>	M362NFI1PjV4N{S2
OVCAR-3	M3PRSWNmdGxiVnnhZoltcXS7IFHzd4F6	NVj2TpJMOTBiwsXN	M2PqRlEhcA>?		MmXI[Y5p[W6lZYOgdIFkdGm2YYjlcE1qdmS3Y3XkJI93[XKrYX6gZ4Fv[2W{IHPlcIwh\GWjdHlCpC=>	MnG4NlQ2OjB{Mke=
OVCAR-3	NYXEWJJsSXCxcITvd4l{KEG\|c3H5	NF33T5EyOCEEtV2=	M1HTPFEhcA>?		MULwdo9ud3SnczDwZYNtcXSjeHXsMYlv\HWlZXSgZZBweHSxc3nzxsA>	MVWyOFUzODJ{Nx?=
OVCAR-3	NHftTWNHfW6ldHnvckBCe3OjeR?=	M1LQTFExKML3TR?=	MV2xJIg>		M37aN4VvcGGwY3XzJJBi[2yrdHH4[YwucW6mdXPl[EBi[3SrdnH0bY9vKG:oIHPhd5Bie2VvOdMg	MYiyOFUzODJ{Nx?=
OVCAR-3	MkfQSpVv[3Srb36gRZN{[Xl?	MVmxNEDDvU1?	MWOxJIg>		NIf0Todld3ewLYLl[5Vt[XSnczDOSk3PwkJiYXP0bZZifGmxbjDpcoR2[2WmIHL5JJBi[2yrdHH4[Yw>	MXWyOFUzODJ{Nx?=
OVCAR-3	MVnGeY5kfGmxbjDBd5NigQ>?	NU\nfmVLOTBiwsXN	Mm\INUBp		NYTseFJucW6qaXLpeJMheGGlbHn0ZZhmdC2rbnT1Z4VlKEGtdDDwbI9{eGixconsZZRqd25?	M1zySFI1PTJyMkK3
CF33	Ml31SpVv[3Srb36gRZN{[Xl?	MoL3NVAxKM7:TR?=	MX:yOEBp		M3HRc4lv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gR29ZNTJicILveIVqdiCneIDy[ZN{cW:w	NWjpWohoOjR3MEO3PFI>
CF33	NEO2PVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7INVAuOTByIN88US=>	MkX4NE01KGR?		MkLDbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NFTyelEzPDVyM{e4Ni=>
CF33	NIX0OYlHfW6ldHnvckBCe3OjeR?=	NVjtR4dGOTBvMUCwJO69VQ>?	MkXyOE0zPCCq		MlfW[IVkemWjc3XzJINmdGy\|IHnuJJRp\SCVIIDoZZNmKGGwZDDpcoNz\WG\|ZYOgZ4VtdHNiaX6gS\|AwTzFiYYLy[ZN1	MkfINlQ2ODN5OEK=
LNCaP	NYXnN3dHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnfUNk82NzFyIN88US=>	NXjHTZNbQTZiaB?=		Mn[3bY5pcWKrdIOgZ4VtdCCpcn;3eIghe2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKGG2b4L2ZZN1[XSrbh?=	M1HPfFI1Ojl4OUe4
LNCaP	M{HmNWFxd3C2b4Ppd{BCe3OjeR?=	MkHsNk82NzFyIN88US=>	MlewPVYhcA>?		MmHBbY5lfWOnczDhdI9xfG:\|aYOgZ49u[mmwZXSge4l1cCCjdH;yeoF{fGG2aX6=	NUjmS\|JUOjR{OU[5O\|g>
PC-3	M4fGXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlnBNE02OCEQvF2=	NED5UGs1QOLCiXi=		NVL5UYdRcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NY\3XZd6OjRzMke4PFI>
PC-3	NXrEbWdqS2WubDDWbYFjcWyrdImgRZN{[Xl?	M33ZUFAuOTByIN88US=>	MYK3NkBp		MYXk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	M37PZVI1OTJ5OEiy

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Fibronectin / Vimentin / N-cadherin / E-cadherin ; PubMed: 28978083 Oncotarget (A) Celecoxib treatment reduces the mesenchymal phenotype in SUM149 cells. COX-2; PubMed: 29515134 Sci Rep L02 cells exposed to PA (200 μM) with different concentrations of celecoxib (Cel, 5-40 μM) for 24 h. Celecoxib decreased protein expression of COX-2 compared with control as indicated by western blot. pAKT / AKT / PPARγ / PTEN ; PubMed: 24721996 Oncotarget Immunoblots from N1-S1 cells treated with different dose celecoxib for 48 h.	28978083 29515134 24721996
Immunofluorescence	PPARγ / PTEN ; PubMed: 24721996 Oncotarget Immunofluorescence analysis in N1-S1 cells treated with 10 μM celecoxib for 48 h.	24721996
Growth inhibition assay	Cell viability; PubMed: 28521485 Oncol Lett Celecoxib caused the concentration-dependent inhibition of (A) GBC-SD and (B) NOZ cell growth.	28521485

In vivo

Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. ^[1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). ^[3]

Protocol

Kinase Assay:^[1]	+ Expand COX enzyme assay in vitro: Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.
Cell Research:^[2]	+ Expand Cell lines: HNE1 and CNE1-LMP1 Concentrations: 0-75 μM Incubation Time: 48 hours Method: The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times. (Only for Reference)
Animal Research:^[1]	+ Expand Animal Models: A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats. Formulation: Celecoxib is dissolved in 0.5% methyl cellulose and 0.025% Tween-20. Dosages: ≤200 mg/kg Administration: Administered via p.o. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	76 mg/mL (199.28 mM)
	Ethanol	33 mg/mL (86.53 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Celecoxib SDF

Molecular Weight	381.37
Formula	C₁₇H₁₄F₃N₃O₂S
CAS No.	169590-42-5
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	SC 58635

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03896113	Not yet recruiting	Drug: Celecoxib 200mg capsule	Endometrium Cancer	Cliniques universitaires Saint-Luc- Université Catholique de Louvain	June 30 2019	Phase 2
NCT03643744	Recruiting	Drug: Celecoxib 200mg\|Drug: Placebo	Actinic Keratosis\|Photodynamic Therapy	Jeffrey B. Travers MD PhD\|Wright State Physicians	April 1 2019	Phase 1
NCT01344200	Not yet recruiting	Drug: Celecoxib	Pharmacokinetics of Celecoxib in Children	Children''s Hospital of Eastern Ontario	March 2019	Phase 4
NCT02876094	Recruiting	Drug: celecoxib	Spinal Muscular Atrophy (SMA)	Hugh McMillan\|Families of Spinal Muscular Atrophy\|Gwendolyn Strong Foundation\|Children''s Hospital of Eastern Ontario	January 29 2019	Phase 2
NCT03672162	Recruiting	Procedure: Total abdominal hysterectomy	Total Abdominal Hysterectomy Pain Acute PostoperativeGabapentin Celecoxib	Rajavithi Hospital	September 1 2018	Not Applicable
NCT03541655	Active not recruiting	Drug: Bupivacaine HCl\|Drug: F14 (celecoxib)	Total Knee Replacement\|Postoperative Pain	Arthritis Innovation Corporation	May 4 2018	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I am doing an animal experiment with mice and planning to administrate S1261 via oral gavage. what are your recommendations for diluting the compound?
Answer:
For oral administration, Celecoxib can be dissolved in vehicle one: "0.5% methyl cellulose and 0.025% Tween-20", or the vehicle 2 "2% DMSO/30% PEG 300/5% Tween 80/ ddH2O".

COX Signaling Pathway Map

COX Inhibitors with Unique Features

Pan COX inhibitor

Naproxen : Pan-COX inhibitor, COX-1, IC50=8.7 μM; COX-2, IC50=5.2 μM.
Most Potent COX Inhibitor

Lornoxicam : COX-1, IC50=5 nM; COX-2, IC50=8 nM.
FDA-approved COX Inhibitor

Ibuprofen : Approved by FDA for relieving pain, alleviating fever,and reducing inflammation.
Classic COX Inhibitor

Ketorolac : Non-selective COX inhibitor of COX-1 and COX-2 with IC50 of 1.23 μM and 3.50 μM, respectively.

Related COX Products

Xanthohumol ^New

Xanthohumol, a prenylated chalcone from hop, inhibits COX-1 and COX-2 activity and shows chemopreventive effects. Phase 1.
AZD3839 ^New

AZD3839 is a potent and selective BACE1 inhibitor with K_i of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1.
A-438079 HCl ^New

A-438079 HCl is a potent, and selective P2X7 receptor antagonist with pIC50 of 6.9.
Indomethacin

Indomethacin is a nonselective COX1 and COX2 inhibitor with IC50 of 0.1 μg/mL and 5 μg/mL, respectively, used to reduce fever, pain, stiffness, and swelling.
Lornoxicam

Lornoxicam is a non-steroidal COX-1/COX-2 inhibitor, used as an anti-inflammatory drug to treat pain, osteoarthritis, and rheumatoid arthritis.
Aspirin

Aspirin is a salicylate, and irreversible COX1 and COX2 inhibitor, used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication.
Rofecoxib

Rofecoxib is a COX-2 inhibitor with IC50 of 18 nM.
Ketorolac

Ketorolac is a non-selective COX inhibitor of COX-1 and COX-2 with IC50 of 1.23 μM and 3.50 μM, respectively.

Features:A COX-1 preferential inhibitor among currently marked nonsteroidal anti-inflammatory drugs (NSAIDs).
Bufexamac

Bufexamac is a COX inhibitor for IFN-α release with EC50 of 8.9 μM.

Features:A specific inhibitor of class IIB histone deacetylases.
Ibuprofen

Ibuprofen (Dolgesic) is an anti-inflammatory inhibitor targeting COX-1 and COX-2 with IC50 of 13 μM and 370 μM, respectively.

Features:Considered a core medicine in the WHO's "WHO Model List of Essential Medicines" (a list of the minimum medical requirements for a basic healthcare system).

Choose Your Country or Region

By Signaling Pathways

By product type